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Abstract
Alcohol intake affects in great the symptoms and life of  psoriasis patients, although the association of SNPs related to 
increased alcohol consumption with psoriasis has not been elucidated. Therefore, to investigate the association of psoriasis 
with established alcohol consumption and dependence-related gene variants we conducted a population-based case–control 
study including 3743 subjects (776 psoriasis cases and 2967 controls from the general Hungarian population). Genotyping 
of 23 SNPs at ADH1B, ADH1C, ALDH1A1, ALDH2, SLC6A3, DDC, GABRA2, GABRG1, HTR1B, MAOA, TPH2, CHRM2, 
GRIN2A, POMC, OPRM1, OPRK1 and BDNF were determined and differences in genotype and allele distributions were 
investigated. Multiple logistic regression analyses were implemented. Analysis revealed association between C allele of the 
rs1229984 polymorphism (ADH1B gene) and psoriasis risk  (ORadditive = 1.58, 95% CI 1.23–2.03, p < 0.001,  ORrecessive = 1.58, 
95% CI 1.22–2.04, p = 0.001). Furthermore, the G allele of rs1799971 polymorphism (OPRM1 gene) increased the risk of 
familial aggregation  (ORadditive = 1.99, 95% CI 1.36–2.91, p < 0.001  ORdominant = 2.01, 95% CI 1.35–3.01, p < 0.001). In 
subgroups of psoriatic patients with history of early onset and familial aggregation effect allele ‘C’ of rs1229984 showed 
association in the additive and recessive models  (ORadditive = 2.41, 95% CI 1.26–4.61, p < 0.01,  ORrecessive = 2.42, 95% CI 
1.26–4.68, p < 0.01). While effect allele ‘G’ of rs1799971 (OPRM1) also associated with increased risk of early onset 
and familial aggregation of psoriasis in the additive and dominant models  (ORadditive = 1.75, 95% CI 1.27–2.43, p = 0.001, 
 ORdominant = 1.82, 95% CI 1.26–2.63, p = 0.001). Our results suggest that genetically defined high-risk individuals for alcohol 
consumption are more common in the psoriasis population.
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Introduction
Psoriasis is a common chronic inflammatory disease affect-
ing 1–4% of the world population, with strong genetic 
as well as environmental factors in the background [32] 
affecting the onset, clinical manifestation and the course 
of the disease [6]. While the genetic association with the 
HLA-Cw6 allele and the nearly 40 risk regions revealed by 
recent GWAS studies confirm a pivotal role for the immune 
system [31, 33], the extent and mechanisms for gene-envi-
ronment interactions in contributing to the pathogenesis or 
the increased risk for various comorbidities remains to be 
elucidated.
Alcohol consumption is one of the primary environmental 
factors, showing a direct link with psoriatic risk [3, 11, 20, 
37, 49, 50], although further studies are needed to confirm 
if excessive alcohol consumption correlates with disease 
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severity [17, 27, 36, 51]. Alcohol intake may affect psoria-
sis at various levels from the lower compliance of alcoholic 
patients to its interaction with the metabolism of therapeutic 
drugs [18]. Moreover, alcohol was shown to have a direct 
effect on immune cells and keratinocytes promoting their 
psoriasis related phenotype [12–14]. Still, at least to our 
knowledge, no studies were carried out to investigate the 
possible genetic background for alcohol consumption in 
psoriasis populations, to explore whether psoriatic patients 
have a genetically increased risk for alcohol consumption.
Heritability in alcohol dependence is independent of gen-
der and is estimated to range from 40 to 70% based on twin 
and adoption studies [10, 48]. Most of the genes and their 
polymorphisms that have been linked to alcohol dependence 
both in a predisposing as well as a protective way are related 
to alcohol metabolism and neurotransmission [7, 46].
In this study, the genetic susceptibility to harmful alcohol 
consumption in Hungarian psoriasis patients was compared 
to subjects of general population, by analyzing and com-
paring the frequencies of 23 alleles associated with alcohol 
consumption behaviors based on literature review and recent 
publication [7]. We aimed to address if genetic factors driv-
ing alcohol consumption could be linked to psoriasis, or 
whether primarily environmental factors contribute to the 
increased alcohol consumption of psoriatic patients [9].
Materials and methods
Study population and characteristics
A total of 776 patients (580 patients from Debrecen region 
and 196 patients from Budapest region) diagnosed with 
psoriasis vulgaris and 2967 individuals from the Hungarian 
general population (HG) were enrolled in the study.
The diagnosis of psoriasis was approved by at least two 
dermatologists. Data including family history (familial 
aggregation was positive if psoriasis existed in at least one 
more case among first degree relatives extended with grand-
parents in familial anamnestic data) and age at onset (early 
onset: ≤ 40 years, late onset > 40 years) were collected and 
their association with HLA-Cw*0602 allele was defined. To 
assess the severity of psoriasis Psoriasis Area and Severity 
Index (PASI) score was used. Symptoms were dichotomized 
as follows: in case of patients receiving only topical treat-
ment and/or PASI < 10 without therapy was specified as 
mild psoriasis, ≥ 10 as severe psoriasis. Patients receiving 
systemic therapy were all included in the severe psoriasis 
group independent of the recent PASI score.
Sample representative of the HG population in terms of 
geographic, age and sex distributions were obtained from a 
population-based disease registry, the General Practitioners’ 
Morbidity Sentinel Stations Programme (GPMSSP) [43]. 
Our study involved HG subjects investigated during a recent 
cross-sectional survey. Details of sampling methodology and 
data collection are described elsewhere [44].
Informed consent was obtained from all individual 
participants included in the study. The study protocol 
was approved by the Regional Institutional Scientific and 
Research Ethical Board of the University of Debrecen and by 
the Semmelweis University, Budapest, Hungary in accord-
ance with the principles from the Declaration of Helsinki.
SNP selection
A recent study conducted systematic literature review (Pub-
Med) to identify SNPs of candidate genes most likely to be 
associated with the characteristics of alcohol consumption 
by encoding enzymes involved in alcohol metabolism and 
in pathways related to dependence [7]. Our study utilized 
the same collection set: alcohol dehydrogenase (ADH1B, 
ADH1C), aldehyde dehydrogenase (ALDH1A1, ALDH2) 
and neurotransmitters in the dopaminergic (SLC6A3, 
DDC), GABAergic (GABRA2, GABRG1), serotonergic 
(HTR1B, MAOA, TPH2), cholinergic (CHRM2), glutamater-
gic (GRIN2A) and opioidergic (POMC, OPRM1, OPRK1) 
pathways, as well as one SNP in the gene encoding a protein 
involved in neural development and dendritic growth neuro-
genesis (BDNF) (Supplementary Table 1).
DNA preparation
DNA isolation was performed from ethylenediamine-
tetraacetic acid-anticoagulated blood samples using the 
MagNA Pure LC DNA Isolation Kit—Large Volume (Roche 
Diagnostics, Mannheim, Germany) according to the manu-
facturer’s protocol. The extracted DNA samples were eluted 
in MagNA Pure LC DNA Isolation Kit-Large Volume Elu-
tion Buffer (Roche Diagnostics) and stored in − 30 °C until 
measurements.
Genotype assessment
Genotyping of the selected 23 SNPs was performed by 
Mutation Analysis Core Facility (MAF) of Clinical Research 
Center, Karolinska University Hospital (Stockholm, Swe-
den) using the Mass Array platform with iPLEX Gold 
Chemistry (Sequenom). The validation, concordance analy-
sis and quality control were conducted by MAF according to 
their protocol, resulting in a successful genotyping outcome 
for 3433 (776 psoriatic and 2917 HG) DNA samples. HLA-
Cw*0602 typing was carried out as described previously 
[34].
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Statistical analyses
The data were analyzed using STATA 12.0 Statistical 
software (StataCorp LP, College Station, TX, USA). The 
Mann–Whitney U and χ2 tests were used to compare the 
mean age and sex distribution of the two study groups. The 
existence of Hardy–Weinberg equilibrium (HWE) and sig-
nificant differences in the allele and genotype frequencies 
between the two populations were examined with the χ2 
test. To decrease the proportion of false positive results the 
p threshold of 0.002 was applied (Bonferroni correction); 
otherwise the threshold for significance was 0.05.
To take account of confounding effects of gender and age 
on differences between study populations, linear regression 
models were constructed. Psoriatic samples were divided 
into several subgroups defined by the clinical parameters 
such as familial aggregation, age at onset, and severity 
as described previously. Association analyses were done 
according to additive, dominant and recessive models. To 
further confirm the findings two psoriatic populations from 
Hungary (Budapest vs. Debrecen) were also compared.
To assess whether any allele frequency differences exist 
between the Debrecen and the Budapest subgroups of the 
patients χ2 tests were performed. Similar genotype distribu-
tion of the SNPs were found in these subgroups, suggest-
ing that the association of psoriasis with the identified risk 
alleles in the Hungarian psoriatic patients, is independent of 
the regional origin of the patients.
To assess gene–gene interactions between HLA-Cw*0602 
and the ADH1B and OPRM1 genes PLINK software epista-
sis command was used [38].
Results
Comparison of psoriasis population to Hungarian 
general population
The mean age was 49.15 years ± 16.82 in the case of pso-
riatic patients and 45.53 years ± 14.62 in the case of the 
HG population. The mean age of the study groups was sig-
nificantly different according to the Mann–Whitney U test 
(p < 0.001). The proportion of male individuals in psoriatic 
sample was significantly higher (psoriatic: 60.6% vs. HG: 
46.8%, p < 0.001).
Out of the 23 SNPs investigated, the genotype distribu-
tion of rs1386496 (TPH2 gene) deviated from Hardy–Wein-
berg equilibrium in the HG group (p < 0.001) and was thus 
excluded from further analysis. Allele frequencies in the 
study populations, which were calculated on the basis of 
the obtained genotype distributions, are shown in Table 1. 
ALDH2 rs671 and SLC6A3 rs6530 were monomorphic in 
both groups, and were consequently excluded from further 
analyses.
Differences between the psoriatic and HG population 
remained significant only for one SNP (rs1229984) after 
multiple test correction. Comparing the allele frequency 
distribution of SNP rs1229984 in the gene coding alcohol 
dehydrogenase 1B (ADH1B) significantly higher prevalence 
of effect allele C was found in the psoriatic population com-
pared to the HG population (94.46% vs. 92.04%, p < 0.001, 
respectively). Significant differences were observed between 
study groups in the association analysis according to the 
additive  (ORadditive = 1.58, 95% CI 1.23–2.03, p < 0.001) and 
the recessive model  (ORrecessive = 1.58, 95% CI 1.22–2.04, 
p = 0.001) but not the dominant model  (ORdominant = 4.29, 
95% CI 0.55–33.08, p = 0.163) (Table 1).
Stratified analysis of psoriasis group
By comparing the psoriasis subgroups several strata of pso-
riatic patients were defined, such as familial aggregation vs. 
sporadic case, early-onset of disease (≤ 40 years) vs. late-
onset (> 40 years) and mild (PASI score < 10) vs. severe 
psoriasis symptoms (PASI score ≥ 10 or receiving systemic 
therapy). The number of psoriatic subjects in the subgroup 
analysis (Supplementary Table 2) were sufficient to attain 
power of 80% and to detect an OR of 1.9 (assuming at least 
case–control ratio of 1.8 and alfa = 0.05). The statistical 
power was calculated using Epiinfo 7.2 StatCalc calculator.
Significant results were found only in case of one SNP, 
rs1799971 (μ-opioid receptor gene, OPRM1) when familial 
cases were compared to sporadic cases, The effect allele 
G increased the risk of familial psoriasis by twofold com-
pared to sporadic cases both in additive and in dominant 
models  (ORadditive = 1.99, 95% CI 1.36–2.91, p < 0.001, 
 ORdominant = 2.01, 95% CI 1.35–3.01, p < 0.001) (Table 2),
When creating an additional subgroup from psori-
atic patients with history of early onset (≤ 40 years) and 
familial aggregation and comparing it to the HG popula-
tion, in case of the rs1229984 (ADH1B) and rs1799971 
(OPRM1) significant associations were found. The effect 
allele ‘C’ (rs1229984) both in the additive and reces-
sive models, increased the risk of psoriasis similarly to 
the finding represented in Table 1. However, in the sub-
group analysis the OR was much larger  (ORadditive = 2.41, 
95% CI 1.26–4.61, p < 0.01,  ORrecessive = 2.42, 95% CI 
1.26–4.68, p < 0.01, Table 3). Furthermore, the G allele of 
the rs1799971 (OPRM1) was also significantly associated 
with increased psoriasis risk in the additive and dominant 
models  (ORadditive = 1.75, 95% CI 1.27–2.43, p = 0.001, 
 ORdominant = 1.82, 95% CI 1.26–2.63, p = 0.001) (Table 3).
Familial aggregation and early onset of psoriasis inevitably 
suggest the involvement of genetic factors and is highly asso-
ciated with HLA-Cw*0602. In our cohort, psoriatic patients 
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Table 1  Effect allele frequency distribution of the investigated SNPs
Gene SNP Effect allele Effect allele frequency 
among psoriasis patients, 
N = 776
Effect allele frequency 
in general population, 
N = 2967
p Model OR (95% CI) p
POMCs rs1866146 G 0.3807 0.3955 0.299 ADD 0.94 (0.83–1.06) 0.3295
DOM 0.85 (0.72–1.01) 0.059
REC 1.08 (0.86–1.36) 0.505
POMC rs6713532 C 0.2627 0.2619 0.951 ADD 0.999 (0.87–1.14) 0.9885
DOM 1.06 (0.89–1.25) 0.518
REC 0.79 (0.55–1.12) 0.185
GABRG1 rs2221020 C 0.5183 0.5176 0.958 ADD 0.99 (0.89–1.12) 0.9233
DOM 0.94 (0.78–1.14) 0.525
REC 1.04 (0.87–1.25) 0.652
GABRA2 rs567926 G 0.3997 0.3954 0.762 ADD 1.01 (0.90–1.14) 0.8607
DOM 1.05 (0.88–1.25) 0.5801
REC 0.96 (0.76–1.2) 0.694
GABRA2 rs279871 T 0.6112 0.6126 0.92 ADD 0.99 (0.88–1.12) 0.9327
DOM 1.13 (0.89–1.43) 0.3079
REC 0.93 (0.78–1.10) 0.3799
GABRA2 rs279858 C 0.3914 0.3869 0.751 ADD 1.02 (0.90–1.15) 0.7629
DOM 1.11 (0.93–1.31) 0.2532
REC 0.89 (0.71–1.13) 0.3399
ADH5 rs1154400 C 0.3377 0.3405 0.843 ADD 0.97 (0.86–1.10) 0.6861
DOM 0.98 (0.83–1.17) 0.8557
REC 0.93 (0.71–1.21) 0.573
ADH4 rs7694646 A 0.3191 0.3043 0.272 ADD 1.07 (0.94–1.21) 0.3234
DOM 1.06 (0.90–1.25) 0.5137
REC 1.06 (0.89–1.53) 0.278
ADH4 rs1800759 G 0.5885 0.5932 0.746 ADD 0.9991(0.89–1.13) 0.9888
DOM 0.86 (0.69–1.07) 0.1691
REC 1.098 (0.92–1.30) 0.2906
ADH1B rs1229984 C 0.946 0.9204 0.001 ADD 1.58 (1.23–2.03) 0.000371
DOM 4.29 (0.55–33.08) 0.163
REC 1.58 (1.22–2.04) 0.001
ADH7 rs1154458 C 0.4207 0.412 0.543 ADD 1.06 (0.95–1.20) 0.3015
DOM 1.05 (0.88–1.25) 0.5672
REC 1.14 (0.92–1.41) 0.2906
SLC6A3 rs463379 G 0.7849 0.7746 0.396 ADD 1.05 (0.91–1.21) 0.5035
DOM 1.56 (1.01–2.40) 0.04589
REC 0.99 (0.84–1.18) 0.9367
HTR1B rs130058 T 0.7167 0.7234 0.608 ADD 0.96 (0.85–1.10) 0.582
DOM 1.08 (0.79–1.47) 0.631
REC 0.92 (0.78–1.09) 0.3355
OPRM1 rs1799971 G 0.132 0.1311 0.927 ADD 0.99 (0.83–1.18) 0.8785
DOM 1.01 (0.83–1.22) 0.9315
REC 0.69 (0.31–1.51) 0.3493
DDC rs3779084 G 0.21 0.2019 0.487 ADD 1.06 (0.93–1.21) 0.37
DOM 1.05 (0.88–1.25) 0.6003
REC 1.2 (0.89–1.60) 0.2352
CHRM2 rs324650 A 0.5026 0.5117 0.531 ADD 0.96 (0.85–1.08) 0.4842
DOM 0.94 (0.78–1.14) 0.5233
REC 0.95 (0.79–1.15) 0.6137
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Table 1  (continued)
Gene SNP Effect allele Effect allele frequency 
among psoriasis patients, 
N = 776
Effect allele frequency 
in general population, 
N = 2967
p Model OR (95% CI) p
OPRK1 rs6985606 T 0.4735 0.4734 0.994 ADD 1.004 (0.89–1.13) 0.9522
DOM 1.01 (0.84–1.22) 0.8812
REC 0.99 (0.81–1.21) 0.9533
ALDH1A1 rs610529 G 0.4397 0.4467 0.63 ADD 0.98 0.87–1.10) 0.7383
DOM 1.05 (0.88–1.26) 0.6057
REC 0.88 (0.71–1.09) 0.2373
BDNF rs6265 C 0.8197 0.8003 0.093 ADD 1.15 (0.98–1.33) 0.08108
DOM 1.27 (0.79–2.05) 0.3276
REC 1.16 (0.97–1.38) 0.09954
GRIN2A rs2072450 C 0.8687 0.8641 0.646 ADD 1.17 (0.90–1.27) 0.443
DOM 1.3 (0.69–2.42) 0.4179
REC 1.06 (0.87–1.29) 0.549
MAOA rs979606 T 0.6849 0.6832 0.916 ADD 1.013 (0.873– 1.176) 0.862
DOM NAa NAa
REC NAa NAa
Multiple test correction revealed significant differences for rs1229984 (ADH1B) between the psoriatic and HG population
a NA not applicable, rs979606 was X-linked
Table 2  Association of rs1799971 with psoriasis vulgaris analysed by subgroups (onset, familial vs. sporadic and severity)
Significant results for rs1799971 (OPRM1) were found when familial cases were compared to sporadic cases (highlighted in bold)
Phenotype groups Additive (GG vs. AA) p value Recessive (GG 
vs. GA + AA)
p value Dominant 
(GG + GA vs. 
AA)
p value
OR (95% CI) OR (95% CI) OR (95% CI)
Early-onset psoriasis (≤ 40 years) vs. late -onset (> 40 
years)
0.66 (0.44–1.01) 0.054 1.17 (0.17–7.85) 0.871 0.62 (0.39–0.97) 0.035
Familial psoriasis vs. sporadic psoriasis 1.99 (1.36–2.91) 0.0003 4.53 (0.77–26.4) 0.092 2.01 (1.35–3.01) 0.0006
Severe psoriasis (PASI ≥ 10) vs. mild psoriasis 
(PASI < 10)
0.97 (0.65–1.45) 0.900 0.79 (0.13–4.85) 0.808 1.05 (0.68–1.59) 0.829
Table 3  Associations of rs1799971 and rs1229984 in case of additional psoriasis vulgaris subgroups (history of early onset (≤ 40 years) and 
familial aggregation) compared to the general population
In case of rs1229984 (ADH1B) and rs1799971 (OPRM1) significant associations were found when the subgroup from psoriatic patients with his-
tory of early onset (≤ 40 years) and familial aggregation was compared to the HG population (highlighted in bold)
SNP Effect alelle Phenotype groups vs. 
HG
Additive (GG/CC vs. 
AA)
p value Recessive (GG/
CC vs. GA/
CA + AA)
p value Dominant (GG/
CC + GA/CA vs. 
AA)
p value
OR (95% CI) OR (95% CI) OR (95% CI)
rs1799971 G Early-onset (≤ 40 years) 
+ familial aggregation 
vs. general population
1.75 (1.27–2.43) 0.001 2.57 (0.87–7.62) 0.088 1.82 (1.26–2.63) 0.001
rs1229984 C Early-onset (≤ 40 years) 
+ familial aggregation 
vs. general population
2.41 (1.26–4.61) 0.008 2.42 (1.26–4.68) 0.008 1.08 (0.1–2.3) 0.998
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who had a history of familial aggregation, the risk allele of 
HLA-Cw*0602 gene occurred more frequently compared 
to patients having sporadic disease (53.80% vs. 34.78%, 
p < 0.001, respectively), while among patients who had 
early-onset disease the proportion of those having at least one 
HLA-Cw*0602 risk allele was higher compared to those who 
had late onset disease (47.99% vs 28.08%, p < 0.001, respec-
tively) (Supplementary Table 3). However, neither rs1229984 
(ADH1B) nor rs1799971 (OPRM1) showed a significant 
association when subgroups formed on the presence of at least 
one HLA-Cw*0602 allele were compared. Assessing a pos-
sible gene–gene interaction between HLA-Cw*0602 and the 
ADH1B and OPRM1 genes in the early-onset vs. late-onset 
and familial aggregation vs. sporadic subgroups of patients 
no evidence on epistasis was found in any of the subgroups.
Furthermore, there were no differences in the risk allele 
distribution among HLA-Cw*0602 positive men and women 
in case of any SNPs.
Discussion
The association between psoriasis and increased alcohol 
consumption has been reported in several studies, includ-
ing the conclusion that alcohol consumption or abuse is an 
independent risk factor for the development of the disease. 
However, whether this association is driven by genetic fac-
tors has not been answered yet and therefore, in this study 
we evaluated the relationship between 23 SNPs related to 
increased alcohol intake and dependence in a Hungarian 
psoriasis group. We found that the frequency of the genetic 
variant rs1229984 (ADH1B) increased in the whole psoriasis 
group, while genetic variant rs1799971 (OPRM1) showed 
higher prevalence in the familial form of psoriasis patients. 
Importantly, the risk of psoriasis related to these variants 
increased further in the subgroup of psoriatic patients with 
history of early onset and familial aggregation, but with no 
association to the HLA-Cw*0602 allele.
Keeping the limitations in mind, it is intriguing to specu-
late on how the detected SNPs, which are primarily related 
to affecting the behaviour of an individual, may be involved 
also in the pathogenesis of psoriasis.
ADH1B is a key enzyme in the metabolism of ethanol 
to acetaldehyde and subsequent oxidation to acetate. The 
allele G which was increased in the psoriasis population 
leads to an increased enzyme activity, thus to decreased lev-
els of the harmful acetaldehyde following alcohol ingestion. 
In contrast, the protective allele is linked to a high blood 
acetaldehyde concentration, which is accounted to make 
drinking unpleasant, and is behind the “Oriental flushing 
response” characterized by facial flushing, headache, tach-
ycardia, and nausea [19, 30]. These symptoms altogether 
are considered to be a genetic deterrent to heavy drinking 
and alcoholism among East-Asians, where the predisposing 
alleles in rs1229984 of ADH1B is around 10% in contrast to 
the 90% found in the Hungarian and European populations 
[26]. Importantly, ADH1B is expressed not just in the liver 
where the majority of the alcohol metabolism takes place, but 
in the skin as well [5]. Moreover, its metabolite acetaldehyde, 
was found to induce the proliferation [14] and the produc-
tion of pro-inflammatory cytokines in keratinocytes under 
in vitro conditions, that could provide a missing piece in the 
puzzle of how alcohol could increase the severity of psoria-
sis. Based on these data, further studies could reveal impor-
tant keratinocyte specific differences in the allele carrying 
patients. Another interesting aspect for further investigations 
is that ADH1B is most likely capable of metabolizing retinoic 
acid as well which could account for an altered response of 
psoriatic patients to retinoic acid based therapies [29].
OPRM1 encodes the μ-opioid receptor, which upon 
activation by its ligands, such as opioids and analgesic 
agents such as beta-endorphin, modulates the dopamine 
system [22]. It is implicated in complex behavior patterns 
such as alcohol dependence in Caucasian, native American 
tribes as well as in a study group of Asian descends [4, 8, 
23, 24] in alcohol dependence associated impulsivity [35] 
just as in a reduced response to rewarding stimuli [25, 39]. 
Out of the alleles, 118G has the major susceptibility effect. 
In individuals carrying 118G stimulation, sedation, and 
positive mood levels after alcohol intake were significantly 
higher than in controls [39]. These effects are confirmed in 
great by studies on its antagonist, naltrexone, which is pre-
scribed to alcohol dependent people to help them reduce 
cravings, control or abstain from drinking [28]. However, 
there are also studies that did not find a higher risk for 
alcohol dependence among OPRM1 118G-allele carriers, 
just as there are alcohol dependent patients who do not 
observe the beneficial effects of naltrexone [1, 16, 42]. 
Thus, patient characteristics and the genetic/environmental 
settings that modulate the OPRM1 related behavior needs 
to be defined in more details. Regarding psoriasis, there is 
a significant amount of data on the impact of psoriasis on 
health behavior by causing psychological stress and psy-
chosocial disability [15]. However, how neurotransmitters 
are involved in the observed changes and could integrate 
into the psoriasis skin-brain axis has been addressed only 
in limited details [21, 40]. Importantly, opioid receptors, 
besides the CNS, are also expressed in the epidermis (μ 
and κ isoforms) with a possible role in transmitting the 
sensation of itch. While activation of μ-opioid receptors 
induces pruritus, activation of κ-opioid receptors is sug-
gested to have a suppressive effect [2]. Moreover, the 
κ-opioid, but not the μ-opioid receptor was down-regulated 
in psoriasis skin [47]. These results altogether put forward 
the question how itch is affecting the alcohol use of pso-
riasis patients and how the detected risk allele of OPRM1 
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could contribute. Our results, therefore, open new perspec-
tives to stratify psoriasis subgroups also based on itch and 
alcohol use [51]. Moreover, the association between pso-
riasis and the opiate signaling pathway, provides excellent 
start points for further studies on understanding not just 
psoriasis associated stress and related risk behavior but 
also to identify psychiatric disorders that may be linked to 
psoriasis or at least to subsets of psoriatic patients on the 
level of genetic association [41].
A limitation of this study is that although both SNPs 
were confirmed to be significant in our two independent 
Hungarian study subgroups, their prevalence did not reach 
significance values in a psoriasis cohort [33] from Sweden. 
Therefore, these findings call for further studies to map these 
SNPs in a geographic distribution. While, to draw conclu-
sions on the functional relevance of the identified SNPs 
regarding the behavior, and perhaps the symptoms and the 
response to specific therapies such as topical μ-opioid recep-
tor antagonists [45] in a subgroup of psoriatic patients with 
itch, a larger sample size is needed than what we used for 
this study.
In conclusion, our data suggests that genetically defined 
high-risk individuals for alcohol consumption are more 
common among psoriasis patients in the general popula-
tion in Hungary, which calls for further studies on how 
genetic determinants of health behavior could be inte-
grated into the psoriasis—psychic stress—alcohol con-
sumption cycle, just as into psoriasis management.
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